Piper Jaffray Assumes Coverage on Human Genome Sciences (HGSI) with an Overweight; Benlysta's First Mover Advantage Key to $4bn+ Opportunity
Tweet Send to a Friend
Piper Jaffray assumes coverage on Human Genome Sciences (Nasdaq: HGSI) with an Overweight rating. Price target increased from $30 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
